Xbiotech Stock Analysis

XBiotech Stock Analysis Notes

About 35.0% of the company outstanding shares are owned by insiders. The company has Price to Book (P/B) ratio of 1.17. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. XBiotech recorded a loss per share of 1.08. The entity last dividend was issued on the 15th of July 2021. XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company was incorporated in 2005 and is headquartered in Austin, Texas. Xbiotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 96 people. For more information please call John Simard at 512 386 2900 or visit https://www.xbiotech.com.

XBiotech Investment Alerts

XBiotech Upcoming and Recent Events

XBiotech Largest EPS Surprises

View All Earnings Estimates

XBiotech Environmental, Social, and Governance (ESG) Scores

XBiotech Thematic Classifications

XBiotech Stock Institutional Investors

Note, although XBiotech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

XBiotech Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 224.05 M.

XBiotech Profitablity

Management Efficiency

XBiotech has return on total asset (ROA) of (0.1203) % which means that it has lost $0.1203 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1575) %, meaning that it created substantial loss on money invested by shareholders. XBiotech's management efficiency ratios could be used to measure how well XBiotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.11 in 2024. Return On Capital Employed is likely to drop to -0.18 in 2024. Total Current Liabilities is likely to gain to about 9.4 M in 2024, whereas Liabilities And Stockholders Equity is likely to drop slightly above 209.4 M in 2024.

Technical Drivers

As of the 29th of November, XBiotech maintains the Mean Deviation of 3.58, downside deviation of 5.26, and Market Risk Adjusted Performance of 0.111. Relative to fundamental indicators, the technical analysis model lets you check existing technical drivers of XBiotech, as well as the relationship between them.

XBiotech Price Movement Analysis

XBiotech Insider Trading Activities

XBiotech Outstanding Bonds

XBiotech Predictive Daily Indicators

XBiotech Corporate Filings

XBiotech Forecast Models

XBiotech's time-series forecasting models are one of many XBiotech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary XBiotech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how XBiotech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling XBiotech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as XBiotech. By using and applying XBiotech Stock analysis, traders can create a robust methodology for identifying XBiotech entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. XBiotech analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. XBiotech analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

XBiotech stock analysis indicators help investors evaluate how XBiotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading XBiotech shares will generate the highest return on investment. By understating and applying XBiotech stock analysis, traders can identify XBiotech position entry and exit signals to maximize returns.

When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.